BrainStorm Cell Therapeutics Inc.
Solebury Trout Talks: Interview with Ralph Kern, BrainStorm - Part of the NameTag Series
BrainStorm Cell Therapeutics Inc.
ralph_qpmkuq.jpg

Itunes_kzba7m_75awwb_0.jpg

google_podcasts_badge2x_r3ddcn_c8dkjd_0.png

 

Ralph Kern, MD, MHSc, is Chief Operating Officer and Chief Medical Officer at BrainStorm. He brings significant industry and neurodegenerative disease experience to the organization. His biotech experience includes senior medical roles at Genzyme, Novartis, and Biogen. At Novartis he was Vice President and Head of the Neuroscience Medical Team, leading the global launch of Gilenya® in relapsing remitting multiple sclerosis (rrMS). At Biogen he was Senior Vice President and Head of the Worldwide Medical Organization. His team launched Zinbryta® in rrMS and Spinraza® in spinal muscular atrophy (SMA), and developed the medical and scientific strategy for MS, SMA, and Alzheimer’s disease.